RxDoctor Payments DataLook up a doctor →

B Bottenberg, DO

Internal Medicine · Carson City, NVNPI 1942210349

Payments from drug & device makers

$11,361in general payments, 2019–2025

Across 516 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Amgen$1K
  • Novo Nordisk$879
  • Pfizer$739
  • Amarin Pharma, Inc.$643
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$11,18098%
  • Education$1812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,361 in reported general payments places this provider in the 90th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$128,487
Medicare patients
266
Services billed
1,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres13$173,161
MounjaroTirzepatide108$130,973
OzempicSemaglutide68$114,931
EliquisApixaban67$87,849
JardianceEmpagliflozin58$84,784
TrulicityDulaglutide33$56,389
Repatha SureclickEvolocumab45$44,126
EntrestoSacubitril/Valsartan15$26,802
FarxigaDapagliflozin Propanediol17$25,363
XareltoRivaroxaban25$24,728
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$23,351
Praluent PenAlirocumab15$21,906
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$9,833
PremarinEstrogens, Conjugated21$7,581
JanuviaSitagliptin Phosphate13$6,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisSandostatin Lar Depot, Entresto$512$199,96228 claims
Lilly USA, LLCMounjaro, Trulicity$390$187,362141 claims
Novo NordiskOzempic$879$114,93168 claims
PfizerEliquis, Premarin$739$95,43088 claims
Boehringer IngelheimJardiance$364$84,78458 claims
GSKTrelegy Ellipta, Anoro Ellipta$120$33,18432 claims
AstraZenecaFarxiga, Symbicort$1,547$30,10130 claims
Johnson & JohnsonXarelto$92$24,72825 claims
MerckJanuvia$46$6,34513 claims
AbbVieSynthroid$1,447$4,39056 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Carson City

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →